These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38616969)

  • 21. Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial.
    Dai M; Wu Y; Tang Y; Yue W; Yan H; Zhang Y; Tan L; Deng W; Chen Q; Yang G; Lu T; Wang L; Yang F; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Li L; Wang C; Ma X; Zhang D; Yu H; Zhao L; Ren H; Wang Y; Hu X; Zhang G; Du X; Wang Q; Li T;
    BJPsych Open; 2020 Oct; 6(6):e126. PubMed ID: 33090091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
    Glick ID; Lemmens P; Vester-Blokland E
    Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
    Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
    Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.
    Liu-Seifert H; Ascher-Svanum H; Osuntokun O; Jen KY; Gomez JC
    BMC Psychiatry; 2011 May; 11():87. PubMed ID: 21586165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of early response to the antipsychotic treatment and related factors in acute schizophrenia patients].
    Sun MX; Ma J; Wang X; Yang YF; Li WW; Zhang Y; Zhao JY; Du YH; Zhang HX; Zhang D; Lü LX
    Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(31):2425-2430. PubMed ID: 28835042
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
    Pillinger T; McCutcheon RA; Vano L; Mizuno Y; Arumuham A; Hindley G; Beck K; Natesan S; Efthimiou O; Cipriani A; Howes OD
    Lancet Psychiatry; 2020 Jan; 7(1):64-77. PubMed ID: 31860457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
    Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
    CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between Insertion-Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Treatment Response to Antipsychotic Medications: A Study of Antipsychotic-Naïve First-Episode Psychosis Patients and Nonadherent Chronic Psychosis Patients.
    Nadalin S; Dević Pavlić S; Peitl V; Karlović D; Zatković L; Ristić S; Buretić-Tomljanović A; Jakovac H
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
    Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
    Bisol LW; Brunstein MG; Ottoni GL; Ramos FL; Borba DL; Daltio CS; de Oliveira RV; Paz GE; de Souza SE; Bressan RA; Lara DR
    J Clin Psychiatry; 2008 Oct; 69(10):1572-9. PubMed ID: 19192440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.